The global carrier screening market size reached US$ 1.7 Billion in 2022. Looking forward, the market is expected to reach US$ 3.1 Billion by 2028, exhibiting a growth rate (CAGR) of 10.53% during 2022-2028.
Carrier screening is a genetic testing technique used for the identification abnormal genes in fetuses that can cause autosomal recessive diseases. It is a predictive and pre-symptomatic testing solution used by pregnant individuals and couples to analyze the risks of their child inheriting genetic disorders from the parents. It involves testing a sample of saliva, blood or cheek tissue to detect the presence of an abnormal gene for disorders, such as cystic fibrosis, sickle cell anemia and Tay-Sachs disease. These samples are screened through molecular and biochemical processes based on deoxyribonucleic acid (DNA) sequencing, polymerase chain reaction (PCR) and microarray technologies. They are used for expanded, customized panel, predesigned panel and targeted disease carrier screening for various pulmonary, hematological and neurological disorders.
Carrier screening is a genetic testing technique used for the identification abnormal genes in fetuses that can cause autosomal recessive diseases. It is a predictive and pre-symptomatic testing solution used by pregnant individuals and couples to analyze the risks of their child inheriting genetic disorders from the parents. It involves testing a sample of saliva, blood or cheek tissue to detect the presence of an abnormal gene for disorders, such as cystic fibrosis, sickle cell anemia and Tay-Sachs disease. These samples are screened through molecular and biochemical processes based on deoxyribonucleic acid (DNA) sequencing, polymerase chain reaction (PCR) and microarray technologies. They are used for expanded, customized panel, predesigned panel and targeted disease carrier screening for various pulmonary, hematological and neurological disorders.
Carrier Screening Market Trends
The increasing prevalence of fetal chromosomal abnormalities and genetic disorders across the globe is one of the key factors driving the growth of the market. Moreover, the rising consciousness among the masses regarding the benefits of early detection and diagnosis of diseases is providing a thrust to the market growth. In line with this, molecular screening tests are widely conducted to identify DNA mutations in the genetic codes and detect the mutations that can cause heart defects, pre-leukemia, hearing defects and down syndrome. Carrier screening also aids in providing adequate prenatal and reproductive care, which facilitates the proper management of heritable diseases. Additionally, various technological advancements, such as the development of next-generation sequencing (NGS) techniques for genetic disease screening, are also favoring the market growth. Other factors, including extensive research and development (R&D) activities in the field of biotechnology and bioinformatics, along with significant growth in the medical infrastructure, are anticipated to drive the market toward growth.Key Market Segmentation
This research provides an analysis of the key trends in each sub-segment of the global carrier screening market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on type, medical condition, technology and end user.Breakup by Type:
- Expanded Carrier Screening
- Customized Panel Testing
- Predesigned Panel Testing
- Targeted Disease Carrier Screening
Breakup by Medical Condition:
- Pulmonary Conditions
- Hematological Conditions
- Neurological Conditions
Breakup by Technology:
- DNA Sequencing
- Polymerase Chain Reaction
- Microarrays
Breakup by End User:
- Hospitals and Clinics
- Reference Laboratories
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Latin America
- Brazil
- Mexico
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being Fulgent Genetics, Gene By Gene Ltd. (MyDNA), Illumina Inc., Invitae Corporation, MedGenome Labs Ltd., Myriad Genetics Inc., Natera Inc., OPKO Health Inc., Quest Diagnostics, Sema4 and Thermo Fisher Scientific Inc.Key Questions Answered in This Report:
- How has the global carrier screening market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global carrier screening market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the medical condition?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global carrier screening market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Carrier Screening Market
6 Market Breakup by Type
7 Market Breakup by Medical Condition
8 Market Breakup by Technology
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
Companies Mentioned
- Fulgent Genetics
- Gene By Gene Ltd. (MyDNA)
- Illumina Inc.
- Invitae Corporation
- MedGenome Labs Ltd.
- Myriad Genetics Inc.
- Natera Inc.
- OPKO Health Inc.
- Quest Diagnostics
- Sema4
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 147 |
Published | November 2023 |
Forecast Period | 2022 - 2028 |
Estimated Market Value ( USD | $ 1.7 Billion |
Forecasted Market Value ( USD | $ 3.1 Billion |
Compound Annual Growth Rate | 10.5% |
Regions Covered | Global |
No. of Companies Mentioned | 11 |